SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is generating intense discussion as a vocal segment of its community anticipates a "parabolic" price explosion and "third wave rally" following a perceived market correction, urging others to "buy the dip" for what they call a lifetime opportunity. However, a strong counter-narrative views ADA as a "scam" or "rugpull," pointing to long-term underperformance and questioning its leadership amid broader crypto market uncertainty.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently a focal point for crypto enthusiasts, with significant community discussion centered on upcoming developments regarding the 'Clarity Act' and its potential to define the token's regulatory future and market utility. This anticipation, coupled with recent price volatility, has created a polarized environment where strong bullish sentiment about accumulation and an impending 'supply shock' is countered by persistent bearish arguments citing market manipulation and long-term price stagnation despite Ripple's corporate progress.

Secret is the native coin of the Secret Network, a decentralized network for private / secure computation. Nodes on the network (known as secret nodes) can perform generalizable computations over encrypted data, which allows smart contracts (known as secret contracts) to use private and sensitive data as inputs. Our focus is on computational privacy, not just transactional privacy. Developers can build decentralized, privacy-preserving "Secret Apps" on the network. The privacy functionality of the Secret Network is critical for many fields, including decentralized finance, Web3, machine learning, access control, and many more.  The Secret Network is supported by many independent development teams and entities, including Enigma, Secret Foundation, Secretnodes.org, Chain of Secrets, and more

Secret 

Secret Network (SCRT) is gaining attention for its advancements in confidential AI and expanded integrations, bringing privacy-preserving computing to multiple blockchain ecosystems like Arbitrum and ZKsync Era. The community is buzzing about SCRT's long-term potential as a critical Web3 infrastructure, driven by its unique blend of data privacy and AI capabilities, alongside appealing staking rewards.

Gold.com, Inc. engages in the trading of gold, silver, platinum, and palladium bullion numismatic coins, and related products. It operates through the following segments: Wholesale Trading and Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Trading and Ancillary Services segment is involved in the distribution and purchasing of metal products from sovereign and private mints. The Direct-to-Consumer segment provides access to a multitude of products through its wholly owned subsidiaries. The Secured Lending segment includes coin and precious metal dealers, investors, and collectors. The company was founded by Steven C. Markoff on April 9, 1965 and is headquartered in El Segundo, CA.

Gold.com Inc.

Gold.com Inc. (GOLD) is trending due to notable upward price movement and a surge in trading volume, attracting community attention. While the broader commodity gold market is experiencing all-time highs driven by geopolitical factors and safe-haven demand, some observe that the company's stock has underperformed the metals in the past. Investors are also noting its strategic positioning as a precious metals trading company with initiatives in digital gold transactions.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending due to multiple recent analyst upgrades, notably an "Outperform" rating and a $320 price target from Evercore ISI, driven by expectations of robust AI-fueled growth and enhanced ad monetization. The community is keenly discussing its potential as a high-value data provider for AI training, contrasting this bullish outlook with recent market volatility and concerns stemming from some negative ad-performance feedback and insider selling ahead of upcoming earnings.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is trending following its Investor Day, where the company announced a significant $5 billion share buyback program and projected accelerated profit growth, targeting mid-teen gross profit and 30% annual operating income increases through 2028. This outlook, including EPS targets ahead of analyst estimates, is fueling optimism among investors who see a shift towards capital efficiency and ecosystem expansion, though some remain cautious due to past volatility and management's perceived underperformance.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is currently trending following promising clinical data for its Alpha DaRT technology in pancreatic cancer and ahead of its key presentation at a major healthcare conference. The community is actively buzzing about imminent Japanese regulatory approval and rumors of significant institutional investment, alongside the revolutionary potential of its immune-preserving cancer treatment for difficult-to-treat solid tumors.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as the community highlights its significant undervaluation compared to rival DeFi protocols, with active discussion around its robust product development and strategic roadmap. Key talking points include the Aave V4 upgrade, a new savings app aimed at mainstream adoption, and tokenomics enhancements like a proposed annual buyback, positioning AAVE as a leader in real-world asset integration.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind Corp is trending as investors weigh several near-term regulatory catalysts, including an Afrezza label update and pediatric approval, alongside a recent business update reporting record quarterly revenue. Despite these developments, community discussion reflects deep divisions, with optimists anticipating significant growth and potential M&A, while critics express frustration over stock performance, management's past track record, and recent insider share sales.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending after launching its crypto wallet with Tether, enabling direct creator payments, and advancing its Northern Data acquisition, poised to substantially boost its AI and cloud infrastructure. The community anticipates a notable short squeeze, citing high short interest and significant insider ownership, while also highlighting Tether's considerable financial commitments and Rumble's strategic growth into a decentralized creator economy and cloud provider.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKESF News

AKESFAkeso Inc